Recent Updates
Recently added Catalysts

Autologous genetically modified MAGE A10ᶜ⁷⁹⁶T cells

Phase 1

Urothelial Carcinoma | Gene therapy | Oncology |Adaptimmune Therapeutics PLC Sponsored ADR|Last Updated: Feb 4, 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLEDBiomarker
Total Trials1
Total Enrollment10

FDA Designations

No designations recorded

Clinical trial landscape

Autologous genetically modified MAGE A10ᶜ⁷⁹⁶T cells · 1 trial · 4 indications

Phase 1 1
NCT02989064MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck CancersUrothelial Carcinoma
COMPLETED10 Analytics
PHASE1COMPLETED
MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers
Urothelial Carcinoma
NCT0298906410
Unlock trial analytics

Study Endpoints

Primary Endpoints

Number of subjects with adverse events (AE), including serious adverse events (SAE).
3 years

Determine if treatment with autologous genetically modified T cells, (MAGE A10ᶜ⁷⁹⁶T ) is safe and tolerable through laboratory assessments including chemistry, hematology and coagulation; and cardiac assessments, including ECG/troponin.

Evaluation of the persistence of genetically modified T cells
3 years

Evaluation of the persistence of the infused T cells in the periphery.

Measurement of RCL in genetically modified T cells.
3 years

Evaluation of RCL in Subject PBMCs using PCR-based assay.

Assessment of dose limiting toxicities to determine optimally tolerated dose range
3 years

Evaluation of dose limiting toxicities will be performed using the CTCAE Version 4.0

Proportion of subjects with a confirmed Complete Response (CR) and/or Partial Response (PR).
3 years

Evaluation of the efficacy of the treatment by assessment of the Overall Response Rate according to RECIST v1.1

Interval between the date of first T cell infusion dose and first documented evidence of CR or PR.
3 years

Evaluation of the efficacy of the treatment by assessment of time to first response.

Interval between the date of first documented evidence of CR or PR until first documented disease progression or death due to any cause.
3 years

Evaluation of the efficacy of the treatment by assessment of duration of response.

Interval between the date of first documented evidence of SD until first documented disease progression or death due to any cause.
3 years

Evaluation of the efficacy of the treatment by assessment of duration of stable disease.

Interval between the date of first T cell infusion and the earliest date of disease progression or death due to any cause
3 years

Evaluation of the efficacy of the treatment by assessment of progression-free survival.

Interval between the date of first T cell infusion and date of death due to any cause.
3 years

Evaluation of the efficacy of the treatment by assessment of overall survival.

Number and % of subjects having any Long Term Follow Up Adverse Events (AEs)
15 years post last treatment (infusion)

* New occurrence of any malignancy * New occurrence or exacerbation of a pre-existing neurologic disorder * New occurrence or exacerbation of a prior rheumatologic or other autoimmune disorder * New occurrence of a hematologic disorder * New occurrence of any opportunistic and/or serious infections * New occurrence of any unanticipated illness and/or hospitalization deemed related to gene modified cell therapy

Unlock Study Endpoints

Study Design & Arms

AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Autologous genetically modified MAGE A10ᶜ⁷⁹⁶T cellsEXPERIMENTAL -

Interventions

NameTypeDescription
Autologous genetically modified MAGE A10ᶜ⁷⁹⁶T cellsGENETICInfusion of autologous genetically modified MAGE A10ᶜ⁷⁹⁶T on Day 1
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 75 Years
SexALL
Healthy VolunteersNo
Study Sites11

Inclusion Criteria: 1. Subject is ≥18 to ≤75 years of age at the time of signing the study informed consent. 2. Subject has histologically confirmed diagnosis of any one of the following cancers: (A) urothelial cancer (transitional cell cancer of the bladder, ureter or renal pelvis), (B) melanoma, ...

Countries:United StatesCanadaSpain
Unlock Eligibility Criteria